Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics (NCT07519837) | Clinical Trial Compass
RecruitingNot Applicable
Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics
China1,000 participantsStarted 2026-03-18
Plain-language summary
Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fundamentally block or reverse muscle and fat loss. The core challenge lies in the extreme complexity of this pathological mechanism and the lack of early biomarkers.To overcome the limitations of traditional single-dimensional research approaches, this study proposes a combined analysis method utilizing "multi-omics" (imaging omics, pathological omics, metabolomics, and metagenomics) to construct a panoramic systemic model spanning macroscopic clinical manifestations and microscopic molecular processes. The aim is to comprehensively elucidate the pathogenesis and metabolic pathways of cachexia, thereby precisely identifying potential therapeutic targets capable of reversing this pathological process.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years
* Signed informed consent form and voluntary participation in this study
* Histologically and/or cytologically confirmed diagnosis of cancer
* Patients with gastrointestinal malignancies, including:
* Esophageal cancer
* Hepatocellular carcinoma
* Gastric cancer
* Cholangiocarcinoma
* Patients undergoing histopathological examination of primary lesion biopsy or gastrointestinal endoscopic biopsy
Exclusion Criteria:
* Pregnant or lactating women
* Presence of contraindications to surgery
* Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability/unwillingness to cooperate
* Presence of two or more concurrent primary tumors
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in skeletal muscle index (SMI, cm²/m²)
Timeframe: Baseline to 12 months (assessed at 1, 3, 6, and 12 months)